FDA Inspection
GlaxoSmithKline LLCGlaxoSmithKline LLC – FDA Inspection, Apr 19, 2024
Record Details
This FDA Inspection record concerns GlaxoSmithKline LLC, with an inspection on April 19, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · d81fd5bf-3526-4a54-88e1-61ea98c30e1d
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1229588
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
1- 21 CFR 211.198(a)Complaint Handling Procedure
Full citation text and observation details available on the Dashboard.
Other FDA inspections of GlaxoSmithKline LLC
8| Date | Classification | Office | Project area |
|---|---|---|---|
| February 20, 2026 | Not classified | Atlanta District Office | |
| January 26, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 21, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 21, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 3, 2013 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for GlaxoSmithKline LLC
- FDA Inspection 1298596 - 2026-02-20
- FDA Inspection 1043270 - 2018-01-26
- FDA Inspection 987392 - 2016-04-21
- FDA Inspection 940149 - 2015-08-21
- FDA Inspection 841675 - 2013-05-03
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.